Dabucon, Nereka M.
HRN: 25-35-45 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/10/2025
CEFTAZIDIME 1GM (VIAL)
01/10/2025
01/17/2025
IV
2g
OD
Acute Pulmonary Congestion Sec To CKD
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes